The formulation is used to treat diseases associated with inappropriate insulin levels.
Preclinical studies including Phase 1 and multicenter Phase 2 clinical trials have proven the efficacy of the formulation.
Insulin is delivered to the nasal mucosa and does not enter the lungs.
The move is believed to strengthen the insulin patent portfolio in China.